Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia

Liu, Yabo; Li, Huibo; Zhao, Yanqiu; Li, Dandan; Zhang, Qian; Fu, Jinyue; Fan, Shengjin

doi:10.1080/21655979.2021.2024389

Cited by 7 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, HOTAIR might reduce CML cell apoptosis by activating the PI3K/AKT signaling pathway 63 . Some other lncRNAs, such as ADORA2A‐AS1, MALAT1, MEG3, OIP5‐AS1, and SNHG5, also function as microRNA sponges to regulate the expression of genes related to therapy resistance 11,64–67 …”

Section: Roles Of Lncrnas In Resistance To Leukemia Treatmentsmentioning

confidence: 99%

“…63 Some other lncRNAs, such as ADORA2A-AS1, MALAT1, MEG3, OIP5-AS1, and SNHG5, also function as microRNA sponges to regulate the expression of genes related to therapy resistance. 11,[64][65][66][67] To overcome the resistance against imatinib, new generations of TKIs, such as bosutinib, dasatinib, nilotinib, and ponatinib, are developed. Unfortunately, drug resistance against these novel agents has also been reported.…”

Section: F I G U R Ementioning

confidence: 99%

“… 63 Some other lncRNAs, such as ADORA2A‐AS1, MALAT1, MEG3, OIP5‐AS1, and SNHG5, also function as microRNA sponges to regulate the expression of genes related to therapy resistance. 11 , 64 , 65 , 66 , 67…”

Section: Roles Of Lncrnas In Resistance To Leukemia Treatmentsmentioning

confidence: 99%

See 2 more Smart Citations

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Shi

Gao

Zhang³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Section: Roles Of Lncrnas In Resistance To Leukemia Treatmentsmentioning

confidence: 99%

Section: F I G U R Ementioning

confidence: 99%

See 1 more Smart Citation

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Shi

Gao

Zhang³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…and increases proliferation and drug resistance in CML cells [118]. Meanwhile, lncRNA ADORA2A-AS1 is highly expressed in CML cells and can sponge miR-665 and negate its therapeutic effect [95].…”

Section: Circulatory Cancersmentioning

confidence: 99%

Hsa-miR-665 Is a Promising Biomarker in Cancer Prognosis

Guan,

Pavani,

Chunduru

et al. 2023

Cancers

View full text Add to dashboard Cite

Biomarkers are biomolecules used to identify or predict the presence of a specific disease or condition. They play an important role in early diagnosis and may be crucial for treatment. MicroRNAs (miRNAs), a group of small non-coding RNAs, are more and more regarded as promising biomarkers for several reasons. Dysregulation of miRNAs has been linked with development of several diseases, including many different types of cancer, and abnormal levels can be present in early stages of tumor development. Because miRNAs are stable molecules secreted and freely circulating in blood and urine, they can be sampled with little or no invasion. Here, we present an overview of the current literature, focusing on the types of cancers for which dysregulation of miR-665 has been associated with disease progression, recurrence, and/or prognosis. It needs to be emphasized that the role of miR-665 sometimes seems ambiguous, in the sense that it can be upregulated in one cancer type and downregulated in another and can even change during the progression of the same cancer. Caution is thus needed before using miR-665 as a biomarker, and extrapolation between different cancer types is not advisable. Moreover, more detailed understanding of the different roles of miR-665 will help in determining its potential as a diagnostic and prognostic biomarker.

show abstract

“…ADORA2A-AS1 knockdown in K562 and KCL22 cells significantly enhanced the imatinib sensitivity of cells. Functional assays showed that ADORA2A-AS1 facilitated ABCC2 expression in K562 and KCL22 cells via sponging miR-665, indicating that ADORA2A-AS1 may contribute to the development of imatinib resistance by driving ABCC2-mediated drug efflux in CML (198). Moreover, Wang et al demonstrated that lncRNA KCNQ1OT1 significantly increased in temozolomide (TMZ)resistant U251 and U87 cells compared to TMZ-sensitive U251 and U87 cells.…”

Section: Lncrnas Modulate Abc Transporter-mediated Drug Efflux In Can...mentioning

confidence: 99%

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Zhou

Jia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients.

show abstract

Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia

Cited by 7 publications

References 36 publications

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Long non‐coding RNAs regulate treatment outcome in leukemia: What have we learnt recently?

Hsa-miR-665 Is a Promising Biomarker in Cancer Prognosis

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Contact Info

Product

Resources

About